Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects

Drug Metabolism and Disposition

Volumn 30, Issue 4, 2002, Pages 430-437

  Patrick, James E ^a   Kosoglou, Teddy ^a   Stauber, Kathe L ^a   Alton, Kevin B ^a   Maxwell, Stephen E ^a   Zhu, Yali ^a   Statkevich, Paul ^a   Iannucci, Robert ^a   Chowdhury, Swapan ^a   Affrime, Melton ^a   Cayen, Mitchell N ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 O [4 [1 (4 FLUOROPHENYL) 4 OXO 3 [3 HYDROXY 3 (4 FLUOROPHENYL)PROPYL] 2 AZETIDINYL]PHENYL] BETA DEXTRO GLUCURONIC ACID; CARBON 14; CHOLESTEROL; DRUG METABOLITE; EZETIMIBE; SCH 60663; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; AZETIDINES; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; ENTEROHEPATIC CIRCULATION; FECES; HUMANS; MALE; MASS SPECTROMETRY; URINE;

EID: 18344380806     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.4.430     Document Type: Article

References (27)

1. Biliary excretion and pharmacokinetics of ezetimibe in rats and dogs
2. The cholesterol absorption inhibitor ezetimibe (SCH 58235) and lovastatin synergistically lower plasma cholesterol and inhibit the development of atherosclerosis
3. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
4. EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results
5. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
6. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe
7. Growth in use of statins after trials is not targeting to most appropriate patients
8. The effect of bile secretion on the pharmacokinetics of a theophylline sustained-release preparation
9. Noncompartmental analysis based on statistical moment theory
10. Metabolism of SCH 58235 in the human, rat and dog
11. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
12. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH 58235): Pooled analysis of two phase II studies
13. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
14. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers
15. The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
16. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)- (4-hydroxyphenyl)-2-azetidinone (SCH58235): A designed, potent, orally active inhibitor of cholesterol absorption
17. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
18. Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461
19. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
20. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
21. SCH 48461, a novel inhibitor of cholesterol absorption
22. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
23. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461
24. In vitro metabolism of SCH 58235, 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)- (4-hydroxyphenyl)-2-azetidinone, by liver and kidney slices
25. Effect of age on the pharmacokinetics of ezetimibe
26. The effect of gender on the pharmacokinetics of SCH 58235, a cholesterol absorption inhibitor
27. Effect of ezetimibe (SCH 58235) on the activity of drug-metabolizing enzymes in vivo